PMID- 2902125
OWN - NLM
STAT- MEDLINE
DCOM- 19881103
LR  - 20190828
IS  - 0195-6701 (Print)
IS  - 0195-6701 (Linking)
VI  - 12 Suppl D
DP  - 1988 Aug
TI  - Clinical safety of intravenous immune globulin and freedom from transmission of 
      viral disease.
PG  - 17-27
AB  - Although rare, side-effects have been associated with the administration of iv 
      immune globulins (IVIG). While the clinical presentation may be similar, several 
      different mechanisms account for these adverse reactions. There are those effects 
      in the hypogammaglobulinaemic patient which are probably due to antigen-antibody 
      interaction (so-called inflammatory reactions), those due to spontaneous 
      activation of the complement system (possibly caused by IgG aggregates), those 
      due to true hypersensitivity (for example, hypersensitivity to IgA), and those 
      due to possible contaminants or even stabilizers or preservatives which might 
      have been used. The incidence and nature of clinical side-effects seen in 37 
      patients who were treated with a native IVIG is shown. In addition, data are 
      provided which support the absence of transmission of human immune deficiency 
      virus in idiopathic thrombocytopenia (ITP) patients, and the agents of non-A, 
      non-B hepatitis in 41 immune-deficient patients having periods of follow-up 
      ranging up to 18 months. Finally, evidence of the inactivation of human 
      immunodeficiency virus during the manufacturing procedure is provided.
FAU - Rousell, R H
AU  - Rousell RH
AD  - Cutter Biological, Miles Inc., Berkeley, CA 94701.
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Hosp Infect
JT  - The Journal of hospital infection
JID - 8007166
RN  - 0 (Antibodies, Viral)
RN  - 0 (Immunoglobulins)
SB  - IM
MH  - Antibodies, Viral
MH  - Antigen-Antibody Reactions
MH  - Complement Activation
MH  - Consumer Product Safety
MH  - Drug Contamination
MH  - Humans
MH  - Hypersensitivity/immunology
MH  - Immunoglobulins/administration & dosage/adverse effects/*standards
MH  - Infusions, Intravenous
MH  - Virus Diseases/prevention & control/transmission
EDAT- 1988/08/01 00:00
MHDA- 1988/08/01 00:01
CRDT- 1988/08/01 00:00
PHST- 1988/08/01 00:00 [pubmed]
PHST- 1988/08/01 00:01 [medline]
PHST- 1988/08/01 00:00 [entrez]
AID - 0195-6701(88)90026-6 [pii]
AID - 10.1016/0195-6701(88)90026-6 [doi]
PST - ppublish
SO  - J Hosp Infect. 1988 Aug;12 Suppl D:17-27. doi: 10.1016/0195-6701(88)90026-6.